Acute Myeolid Leukemia (AML) Myelodysplastic syndromes (MDS) Multiple Myeloma (MM) Acute Myeloïde Leukemie (AML) Myelodysplastisch syndroom (MDS) Multipel Myeloom (MM) Ziekte van Kahler
Conditions
Interventions
TEG001 infusion (autologous alfa beta T cells Engineerd to express a defined Gamma delta T cell receptor)
Sponsors
University Medical Center Utrecht
Eligibility
Inclusion criteria
Inclusion criteria: - Age ¡Ý 18-years - Relapsed/refractory Acute Myeloid Leukemia, high-risk Myelodysplastic Syndrome (IPSS-R score >4,5) or Multiple Myeloma, for which no remaining standard of care or approved treatment options are available
Exclusion criteria
Exclusion criteria: - In the investigators judgment, the subject is unlikely to complete all protocol-required study visits or procedures - Central Nervous System involvement of the haematological malignancy - Other concurrent malignancy requiring treatment - Treatment with antitumor therapy (conventional or experimental) < 28-days before start of the study treatment - Active endogenous retrovirus - Active GVHD and/or systemic immune suppression; < 28 days before start of the study treatment - Uncontrolled infections - Inadequate renal, hepatic, pulmonary and cardiac function - Pregnant or lactating women
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| The number of patient with one or more Dose Limiting Toxicities | — |
Secondary
| Measure | Time frame |
|---|---|
| 1. number of Adverse Events 2. description of clinical responses 3. levels of TEG001 in peripheral blood | — |
Contacts
Public ContactAnna van Muyden
UMC Utrecht
Outcome results
None listed